Silence Therapeutics PLC Silence to Present at Scientific Conferences
26 March 2018 - 5:00PM
RNS Non-Regulatory
TIDMSLN
Silence Therapeutics PLC
26 March 2018
Silence Therapeutics to Present at Upcoming Scientific
Conferences in March and April 2018
London, 26(th) March 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that that the company is scheduled to
present at the following scientific conferences in March and April
2018.
Third Annual Oligonucleotide & Peptide Therapeutics
(OPT)
March 26-28, 2018, Boston Marriott Cambridge, Cambridge, Boston,
MA, US
Marie Lindholm, Head of Technology Innovation, will present on
Tuesday March 27 at 1.20pm EDT. The presentation is entitled
'Development of Novel Therapies Using Advanced GalNAc-siRNA
Technology'.
Drug Discovery for Rare Diseases Symposium at OPT Congress
March 28, 2018, Boston Marriott Cambridge, Cambridge, Boston,
MA, US
Torsten Hoffmann, COO, will present a case study on the company
and its science entitled 'Identification and Development of SLN124,
a Conjugated GalNAc-siRNA Therapeutic for the Treatment of Iron
Overload Disorders' at 4.35pm EDT.
4(th) Annual Oligo 2018 Oxford
April 10, 2018, St Edmund Hall, Oxford, UK
Adrien Weingaertner, Group Leader, Drug Delivery, will make a
presentation at 5.30pm BST. The presentation is entitled
'Development of innovative hepatocyte-targeted siRNA conjugates for
the treatment of liver-related disorders'.
9th Clinical Trials Innovation Programme
April, 26-27, 2018, Höchster Hof Hotel GmbH, Frankfurt,
Germany
Manuela Aleku, Head of Non-Clinical Development, will be
presenting on Thursday April 26, 2018 at 9am CEST.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Ali Mortazavi, Chief Executive 6900
Officer
David Ellam, Chief Financial
Officer
Peel Hunt LLP (Nominated Tel: +44 (0)20 7418
Adviser and Broker) 8900
James Steel/Oliver Jackson
Media Enquiries:
Optimum Strategic Communications Tel: +44 (0) 20 3714
Mary Clark/ Eva Haas/Hollie 1788
Vile
silence@optimumcomms.com
IR Enquires - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases. For
more information, please visit:
http://www.silence-therapeutics.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFFRVAIVFIT
(END) Dow Jones Newswires
March 26, 2018 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024